Radiotherapy Unit, Campus Bio-Medico University, Rome, Italy.
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):110-5. doi: 10.1016/j.ijrobp.2009.01.036.
To determine lung dosimetric constraints that correlate with radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional radiation therapy and concurrent chemotherapy.
Between June 2002 and December 2006, 97 patients with locally advanced non-small-cell lung cancer were treated with concomitant radiochemotherapy. All patients underwent complete three-dimensional treatment planning (including dose-volume histograms), and patients were treated only if the percentage of total lung volume exceeding 20 Gy (V(20)) and 30 Gy (V(30)), and mean lung dose (MLD) had not exceeded the constraints of 31%, 18%, and 20 Gy, respectively. The total and ipsilateral lung dose-volume histogram parameters, planning target volume, and total dose delivered were analyzed and correlated with pneumonitis incidence.
If dose constraints to the total lung were respected, the most statistically significant factors predicting pneumonitis were the percentage of ipsilateral lung volume exceeding 20 Gy (V(20)ipsi), percentage of ipsilateral lung volume exceeding 30 Gy (V(30)ipsi), and planning target volume. These parameters divided the patients into low- and high-risk groups: if V(20)ipsi was 52% or lower, the risk of pneumonitis was 9%, and if V(20)ipsi was greater than 52%, the risk of pneumonitis was 46%; if V(30)ipsi was 39% or lower, the risk of pneumonitis was 8%, and if V(30)ipsi was greater than 39%, the risk of pneumonitis was 38%. Actuarial curves of the development of pneumonitis of Grade 2 or higher stratified by V(20)ipsi and V(30)ipsi were created.
The correlation between pneumonitis and dosimetric constraints has been validated. Adding V(20)ipsi and V(30)ipsi to the classical total lung constraints could reduce pulmonary toxicity in concurrent chemoradiation treatment. V(20)ipsi and V(30)ipsi are important if the V(20) to the total lung, V(30) to the total lung, and mean lung dose have not exceeded the constraints of 31%, 18%, and 20 Gy, respectively.
确定与三维放射治疗和同期化疗治疗的非小细胞肺癌患者放射性肺炎相关的肺剂量学限制。
2002 年 6 月至 2006 年 12 月,97 例局部晚期非小细胞肺癌患者接受同期放化疗。所有患者均行全三维治疗计划(包括剂量-体积直方图),且只有当总肺体积超过 20 Gy(V(20))和 30 Gy(V(30))的百分比,以及平均肺剂量(MLD)分别不超过 31%、18%和 20 Gy 的限制时,才对患者进行治疗。分析总肺和同侧肺剂量-体积直方图参数、计划靶区和总剂量与肺炎发生率的相关性。
如果总肺的剂量限制得到尊重,预测肺炎的最显著统计学因素是同侧肺体积超过 20 Gy(V(20)ipsi)的百分比、同侧肺体积超过 30 Gy(V(30)ipsi)的百分比和计划靶区。这些参数将患者分为低危和高危组:如果 V(20)ipsi 为 52%或更低,则肺炎的风险为 9%,如果 V(20)ipsi 大于 52%,则肺炎的风险为 46%;如果 V(30)ipsi 为 39%或更低,则肺炎的风险为 8%,如果 V(30)ipsi 大于 39%,则肺炎的风险为 38%。根据 V(20)ipsi 和 V(30)ipsi 分层创建了 2 级或更高放射性肺炎发展的累积曲线。
已经验证了肺炎与剂量学限制之间的相关性。在同期放化疗中,在经典的全肺限制基础上增加 V(20)ipsi 和 V(30)ipsi 可以降低肺毒性。如果全肺的 V(20)、V(30)和平均肺剂量分别不超过 31%、18%和 20 Gy 的限制,则 V(20)ipsi 和 V(30)ipsi 很重要。